Description
Regorafenib (commonly referred to as "Rego") is an oral multikinase inhibitor used as a treatment option for metastatic colorectal cancer in patients who have previously been treated with standard therapies. It is typically reserved for patients whose cancer has progressed after other treatments including fluoropyrimidine, oxaliplatin, irinotecan, and anti-VEGF therapy.
Mechanism of Action
Regorafenib works by blocking multiple protein kinases involved in tumor growth, angiogenesis (blood vessel formation), and metastasis, including VEGFR, PDGFR, FGFR, RET, and RAF kinases.
Side Effects
Hand-foot skin reaction
Fatigue
Diarrhea
Decreased appetite
Hypertension
Voice changes (hoarseness)
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT07213570
Phase 2
Recruiting
STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer
Italy
NCT07003022
Phase 2
Recruiting
Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC
China
NCT06887218
Phase 2
Recruiting
5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
United States
NCT06930118
Phase 2
Recruiting
The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.
China
NCT06992648
Phase 3
Recruiting
Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer
China
NCT06949982
Phase 2
Recruiting
Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes
Russia